Finding Description
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** REPEAT DEFICIENCY
Based on interviews and record reviews, it was determined that the facility failed to accurately code the Minimum Data Set (MDS), an assessment tool used to facilitate the management of care, in accordance with federal guidelines for 1 of 33 residents (Residents #32) reviewed for accuracy of MDS coding.
This deficient practice was evidenced by the following:
On 3/7/25 at 9:58 AM, the surveyor observed Resident #32 in bed awake, able to answer the surveyor's inquiry.
On 3/12/25 at 8:25 AM, the surveyor reviewed the electronic Medical Record (eMR)/ hybrid medical record (paper and electronic) of Resident #32, which revealed the following:
A review of the admission Record (an admission summary) (AR) reflected that Resident #32 was admitted with diagnoses that included but were not limited to schizophrenia (a type of mental illness characterized by distortions in thinking, perception, emotions, language, sense of self and behavior).
A review of the recent Annual MDS (A/MDS), with an assessment reference date (ARD) (the last day of the observation period) of 1/10/25, indicated that the facility assessed the residents' cognitive status using a Brief Interview for Mental Status (BIMS) score of 12 out of 15, which indicated that the resident was moderately impaired in cognition. Further review of the A/MDS and quarterly MDS (Q/MDS) dated [DATE] revealed that both assessments in Section N0450-Antipsychotic Medication Review revealed that A0. No - Antipsychotics were not received.
A review of the Order Summary Report (OSR) with an active order as of 3/12/25 revealed an order of Risperdal (risperidone) 0.5 mg (milligram) by mouth at bedtime related to schizophrenia with an order date of 9/20/24.
A review of the electronic Medication Administration Record (eMAR) in January 2025 revealed that the above order was signed as given by the nurses from 1/4/25 to 1/10/25 at 9:00 PM, and the October 2024 eMAR was signed as given by the nurses from 10/4/24 to 10/10/24 at 9:00 PM respectively.
On 3/12/25 at 10:12 AM, the surveyor interviewed the Unit Manager/Licensed Practical Nurse (UM/LPN), who confirmed to the surveyor that the resident was taking Risperdal starting on 9/20/24.
On 3/12/25 at 10:34 AM, the surveyor interviewed the MDS Coordinator/Registered Nurse (MDSC/RN), who stated that both psychotropic medication assessments were not captured because she accidentally passed the question. She added that the assessment should be yes because the resident had been taking antipsychotic medication since September 2024. The facility followed the RAI (Resident Assessment Instrument-a tool that helps gather information about a resident's strengths and needs, which is used to create an individualized care plan) Manual.
On 3/12/25 at 11:57 AM, the surveyor met with the Licensed Nursing Home Administrator, Director of Nursing, Regional Director of Education and Quality, and Regional Quality Assurance Nurse but did not provide further information.
NJAC 8:39-33.2 (c)
Based on interviews and record reviews, it was determined that the facility failed to accurately code the Minimum Data Set (MDS), an assessment tool used to facilitate the management of care, in accordance with federal guidelines for 1 of 33 residents (Residents #32) reviewed for accuracy of MDS coding.
This deficient practice was evidenced by the following:
On 3/7/25 at 9:58 AM, the surveyor observed Resident #32 in bed awake, able to answer the surveyor's inquiry.
On 3/12/25 at 8:25 AM, the surveyor reviewed the electronic Medical Record (eMR)/ hybrid medical record (paper and electronic) of Resident #32, which revealed the following:
A review of the admission Record (an admission summary) (AR) reflected that Resident #32 was admitted with diagnoses that included but were not limited to schizophrenia (a type of mental illness characterized by distortions in thinking, perception, emotions, language, sense of self and behavior).
A review of the recent Annual MDS (A/MDS), with an assessment reference date (ARD) (the last day of the observation period) of 1/10/25, indicated that the facility assessed the residents' cognitive status using a Brief Interview for Mental Status (BIMS) score of 12 out of 15, which indicated that the resident was moderately impaired in cognition. Further review of the A/MDS and quarterly MDS (Q/MDS) dated [DATE] revealed that both assessments in Section N0450-Antipsychotic Medication Review revealed that A0. No - Antipsychotics were not received.
A review of the Order Summary Report (OSR) with an active order as of 3/12/25 revealed an order of Risperdal (risperidone) 0.5 mg (milligram) by mouth at bedtime related to schizophrenia with an order date of 9/20/24.
A review of the electronic Medication Administration Record (eMAR) in January 2025 revealed that the above order was signed as given by the nurses from 1/4/25 to 1/10/25 at 9:00 PM, and the October 2024 eMAR was signed as given by the nurses from 10/4/24 to 10/10/24 at 9:00 PM respectively.
On 3/12/25 at 10:12 AM, the surveyor interviewed the Unit Manager/Licensed Practical Nurse (UM/LPN), who confirmed to the surveyor that the resident was taking Risperdal starting on 9/20/24.
On 3/12/25 at 10:34 AM, the surveyor interviewed the MDS Coordinator/Registered Nurse (MDSC/RN), who stated that both psychotropic medication assessments were not captured because she accidentally passed the question. She added that the assessment should be yes because the resident had been taking antipsychotic medication since September 2024. The facility followed the RAI (Resident Assessment Instrument-a tool that helps gather information about a resident's strengths and needs, which is used to create an individualized care plan) Manual.
On 3/12/25 at 11:57 AM, the surveyor met with the Licensed Nursing Home Administrator, Director of Nursing, Regional Director of Education and Quality, and Regional Quality Assurance Nurse but did not provide further information.
NJAC 8:39-33.2 (c)